På denne side bringer DANSK BIOTEK nyheder fra medlemmerne, som på denne måde får mulighed for at blive ekstra eksponeret.

Vi modtager derfor gerne pressemeddelelser og andre nyheder. Send dem til Kaya Plewnia, hjælp af denne formular.

28 Sep 2013

US Defense Threat Reduction Agency (DTRA) has selected Evolva to enter into contract negotiations

The US Defense Threat Reduction Agency (DTRA) has announced that it has selected Evolva to enter into contract negotiations regarding possible preclinical funding for Evolva’s antibiotic compound GC-072 (the lead compound in Evolva’s EV-035 series) under the Transformational Medical Technologies Initiative (TMTI). The size of the award could be up to USD 14.7 million. – See more at: http://www.evolva.com/media/press-releases/2013/9/24/evolvas-antibiotic-gc-072-ev-035-series-selected-contract#sthash.36iosbfk.dpuf

If you can't find it here or have feedback to our website, please do not hesitate to contact me on kp@danskbiotek.dk or 28895854

Copyright 2013 Danskbiotek. All rights reserved.